Cargando…
Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
PURPOSE: Cetuximab is an EGFR-targeted therapy approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC). However, about 60% of these patients show innate resistance to cetuximab. To increase cetuximab efficacy, it is crucial to successfully identify responder patients, as...
Autores principales: | Cruz-Duarte, Raquel, Rebelo de Almeida, Cátia, Negrão, Magda, Fernandes, Afonso, Borralho, Paula, Sobral, Daniel, Gallego-Paez, Lina M., Machado, Daniel, Gramaça, João, Vílchez, José, Xavier, Ana T., Ferreira, Miguel Godinho, Miranda, Ana R., Mansinho, Helder, Brito, Maria J., Pacheco, Teresa R., Abreu, Catarina, Lucia-Costa, Ana, Mansinho, André, Fior, Rita, Costa, Luís, Martins, Marta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365369/ https://www.ncbi.nlm.nih.gov/pubmed/34980600 http://dx.doi.org/10.1158/1078-0432.CCR-21-1992 |
Ejemplares similares
-
Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer
por: Leto, Simonetta M., et al.
Publicado: (2023) -
Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAF(V600E)-Mutant Colorectal Cancer
por: Napolitano, Stefania, et al.
Publicado: (2023) -
ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
por: Vokes, Natalie I., et al.
Publicado: (2023) -
PLCβ1-SHP-2 complex, PLCβ1 tyrosine dephosphorylation and SHP-2 phosphatase activity: a new part of Angiotensin II signaling?
por: Calò, Lorenzo A, et al.
Publicado: (2011) -
Escherichia coli ST471 Producing VIM-4 Metallo-β-Lactamase in Colombia
por: Rada, Ana Mercedes, et al.
Publicado: (2022)